Cargando…

Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

Detalles Bibliográficos
Autores principales:	Khalafallah, Alhossain, Brain, Terry
Formato:	Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2010
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033134/ https://www.ncbi.nlm.nih.gov/pubmed/21415965 http://dx.doi.org/10.4084/MJHID.2010.012

Ejemplares similares

An Unusual Presentation of Desmoplastic Small Round Cell Tumour of the Abdomen: Morphological, Immunohistochemical, Ultrastructural, and Molecular Studies
por: Angunawela, Preethika, et al.
Publicado: (2011)

Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy
por: Niscola, Pasquale, et al.
Publicado: (2014)

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities()
por: Dennis, M., et al.
Publicado: (2013)

Myelodysplasia-Related Features of Acute Myeloid Leukemia Evolving From Philadelphia-Negative Myeloproliferative Neoplasms
por: Kim, Jae-Ryuk, et al.
Publicado: (2016)

Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia
por: Cardoso, S R, et al.
Publicado: (2016)

Sustained Viral Response and Hematological Adverse Events in Children With Chronic Hepatitis C
por: Vigano, Alessandra, et al.
Publicado: (2012)

Lenalidomide-induced diffuse alveolar hemorrhage
por: Saheer, S., et al.
Publicado: (2014)

Successful Treatment with Thrombopoietin Receptor Agonist in Avoiding Splenectomy for Patients with Chronic Refractory Immune Thrombocytopenia
por: Khalafallah, Alhossain, et al.
Publicado: (2012)

First Korean case of Emberger syndrome (primary lymphedema with myelodysplasia) with a novel GATA2 gene mutation
por: Seo, Sang Kyung, et al.
Publicado: (2016)

Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation or Treated with Immunomodulatory Agents.
por: Khalafallah, Alhossain, et al.
Publicado: (2010)

Lenalidomide-Induced Pure Red Cell Aplasia
por: Dolai, Tuphan Kanti, et al.
Publicado: (2014)

A case of scleromyxedema responding to lenalidomide and dexamethasone
por: Rambhia, Sweta, et al.
Publicado: (2017)

Outcome of myeloma patients with COVID-19 on active lenalidomide-based therapy: Does lenalidomide protect from severe COVID-19?
por: Tailor, Imran K., et al.
Publicado: (2020)

Sustained Viral Response and Hematological Adverse Events During Chronic Hepatitis C Infection Treatment
por: El-Shabrawi, Mortada, et al.
Publicado: (2012)

Sustained Viral Response Hematological Markers During The Treatment of Chronic Hepatitis C Infection in Children
por: Garcia-Algar, Oscar, et al.
Publicado: (2012)

Mechanism of action of lenalidomide in hematological malignancies
por: Kotla, Venumadhav, et al.
Publicado: (2009)

Expanding role of lenalidomide in hematologic malignancies
por: Ghosh, Nilanjan, et al.
Publicado: (2015)

Is Myelodysplasia a Consequence of Normal Aging?
por: Heibl, Sonja, et al.
Publicado: (2021)

Concurrent Hairy Cell Leukemia and Metastatic Merkel Cell Carcinoma
por: Prakash, Ajay, et al.
Publicado: (2018)

Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma
por: Mandac, Inga, et al.
Publicado: (2010)

Hepatitis B virus‐associated follicular lymphoma presents T‐cell inflamed phenotype and response to lenalidomide
por: Wang, Nan, et al.
Publicado: (2021)

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
por: Kalff, Anna, et al.
Publicado: (2021)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
por: Wang, Chen, et al.
Publicado: (2021)

Temozolomide-Induced Myelodysplasia
por: Natelson, Ethan A., et al.
Publicado: (2010)

Solving the Mystery of Myelodysplasia
por: Radich, Jerald
Publicado: (2008)

Iron Deficiency Anaemia in Pregnancy and Postpartum: Pathophysiology and Effect of Oral versus Intravenous Iron Therapy
por: Khalafallah, Alhossain A., et al.
Publicado: (2012)

Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies
por: McDaniel, Jessica M., et al.
Publicado: (2012)

Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies
por: Blumel, Susan, et al.
Publicado: (2014)

Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk
por: VELİOĞLU, Arzu, et al.
Publicado: (2022)

Glycosylated haemoglobin for screening and diagnosis of gestational diabetes mellitus
por: Khalafallah, Alhossain, et al.
Publicado: (2016)

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial
por: Pettitt, Andrew R., et al.
Publicado: (2020)

Acute Interstitial Nephritis following Lenalidomide Therapy in a Patient with AL Amyloidosis
por: Anandh, Urmila, et al.
Publicado: (2022)

High Serum Erythropoietin and Ferritin Levels in Conjunction with Anemia Response in Malignant Lymphoma
por: Omari, Sofia, et al.
Publicado: (2011)

Antineutrophil cytoplasmic antibodies in myelodysplasia.
por: Hull, D. R., et al.
Publicado: (1996)

Bone Marrow Immunity and Myelodysplasia
por: Lambert, Claude, et al.
Publicado: (2016)

Acquired spherocytosis in the setting of myelodysplasia
por: Karlsson, Linda Katharina, et al.
Publicado: (2022)

Modified dose difference method for comparing dose distributions
Publicado: (2012)

Dyserythropoiesis and myelodysplasia in thiamine‐responsive megaloblastic anemia syndrome
por: Faraji‐Goodarzi, Mojgan, et al.
Publicado: (2020)

An open-label phase I dose-finding study of APR-246 in hematological malignancies
por: Deneberg, S, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ggtknkjn8rli8aj9mg24qs7kai